Study results of Ayurvedic treatment on COVID patients using proprietary herbal formulation SUVED and whole colostrum REIMMUGEN.
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B342- Coronavirus infection, unspecified
- Registration Number
- CTRI/2020/05/025343
- Lead Sponsor
- Health Solutions
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients admitted to COVID ward; symptomatic or non-symptomatic.
Patients under observation in COVID quarantine.
Exclusion Criteria
Below age 18, pregnant and lactating women; Patients in COVID ICU with ventilator support.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MortalityTimepoint: 15 days or at discharge for any reason
- Secondary Outcome Measures
Name Time Method MorbidityTimepoint: 15 days or at discharge for any reason
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie SUVED and REIMMUGEN's antiviral and immune-modulating effects in SARS-CoV-2 infection?
How does the SU-REM-COVID trial compare to standard-of-care therapies like remdesivir in reducing hospitalization duration and mortality for SARS-CoV-2 patients?
Which biomarkers (e.g., cytokine profiles, viral load) correlate with clinical response to SUVED and REIMMUGEN in CTRI/2020/05/025343?
What are the safety profiles and adverse event management strategies for SUVED and REIMMUGEN in SARS-CoV-2-infected individuals?
Are there other Ayurvedic compounds or combination therapies with similar mechanisms to SUVED and REIMMUGEN for treating SARS-CoV-2 infections?